NEOG (Neogen Corporation) — AI Stock Research

Research of October 13, 2026 · Healthcare / In Vitro & In Vivo Diagnostic Substances

TradeFlare's AI research teams rate NEOG a HOLD. The latest price is $11.82.

The research plan

• Entry: $12.00
• Target: $15.00
• Stop: $10.20
• Time horizon: days

The scanner trigger is a short-term PEAD signal, and the market regime is neutral, suggesting a quick decision is best.

Why

The scanner trigger is a short-term PEAD signal, and the market regime is neutral, suggesting a quick decision is best. Catalysts to watch: Post-earnings drift (PEAD) signal from a significant EPS beat; Positive guidance for FY27 and a long-term growth narrative from the Fundamental team; Analyst upgrades and strategic growth initiatives noted by the Sentiment team. Key risks: High risk score (8/10) due to deep 1-year drawdown, high volatility, product recall, regulatory scrutiny, and cash burn concerns; Technical analysis is NEUTRAL with conflicting signals, and the stock is currently in a sideways trend with short-term bearish pressure; The market regime is NEUTRAL, and a flat broad market is not a reason to hold a strong single-stock setup if other factors are not overwhelmingly bullish.

What could push NEOG higher

• Post-earnings drift (PEAD) signal from a significant EPS beat.
• Positive guidance for FY27 and a long-term growth narrative from the Fundamental team.
• Analyst upgrades and strategic growth initiatives noted by the Sentiment team.

Key risks for NEOG

• High risk score (8/10) due to deep 1-year drawdown, high volatility, product recall, regulatory scrutiny, and cash burn concerns.
• Technical analysis is NEUTRAL with conflicting signals, and the stock is currently in a sideways trend with short-term bearish pressure.
• The market regime is NEUTRAL, and a flat broad market is not a reason to hold a strong single-stock setup if other factors are not overwhelmingly bullish.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Neogen presents a speculative investment case with strong revenue growth and positive free cash flow, but current unprofitability and a negative interest coverage ratio are significant headwinds. The company's clear path to margin expansion and positive analyst sentiment offer potential upside, justifying a neutral stance with a speculative valuation view.

• Neogen is currently unprofitable with negative net and operating margins, making its valuation speculative despite positive free cash flow.
• The company exhibits strong revenue growth (6.5% YoY) and improving operational metrics, with positive guidance for FY27 and a long-term target of 30% adjusted EBITDA margins.
• Positive free cash flow generation ($31.9M TTM) and a solid current ratio (3.90) indicate good operational cash generation and short-term liquidity.

Technical team: Neutral

NEOG is currently in a neutral state with conflicting signals across technical indicators. While the long-term trend is supported by the MA200, short-term indicators and momentum are mixed, and no clear chart patterns are present. Further observation is required to confirm a directional bias.

• The stock is in a sideways trend with short-term bearish pressure below MAs, but a long-term bullish backdrop from an upward-trending MA200.
• Volume has been generally low, with a recent increase and mix of green/red bars, indicating indecision and no clear trend confirmation.
• Momentum indicators are mixed, with a bearish MACD signal but neutral RSI and inconclusive Stochastic, suggesting decreasing momentum.

Sentiment team: Neutral

Neogen's sentiment is currently neutral, reflecting a balance between positive news from an earnings beat and analyst upgrades, and concerns around stock volatility, governance issues, and a swing to a quarterly loss. While there are clear catalysts for future growth, the mixed signals and ongoing investigations prevent a strongly bullish or bearish conviction at this time.

• Neogen's news coverage is predominantly neutral, with a slight positive lean driven by recent earnings beats, analyst upgrades, and strategic growth initiatives, though a notable stock price drop and an analyst/investor day indicate a mixed sentiment...
• Neogen (NEOG) exhibits a neutral sentiment driven by a recent earnings beat and positive outlook, offset by concerns regarding executive pay, stock performance, and ongoing investigations. (Score: 0.083)
• Neogen exhibits a positive sentiment driven by a recent earnings beat, analyst upgrade, and strategic growth initiatives, although concerns remain regarding recent stock dips and a swing to a quarterly loss. (Consensus: POSITIVE)

Risk team: High

NEOG presents a high-risk profile due to its extreme historical drawdown, elevated volatility, significant regulatory concerns, and persistent unprofitability. The combination of these factors, amplified by sector-specific risks, necessitates a cautious approach with a small position size and robust risk management strategies.

• Deep 1-Year Drawdown and High Volatility: NEOG has experienced an extreme -81.59% drawdown over the past year, coupled with very high annualized volatilities (58.02% 20d, 62.25% 60d) and a beta of 1.85, indicating significant price instability and...
• Product Recall and Regulatory Scrutiny: A recent FDA warning letter for Hycoat and an ongoing ACCC review of a business sale highlight severe regulatory and product quality risks that could materially impact operations and reputation.
• Cash Burn and Profitability Concerns: Negative trailing EPS (-0.26) and interest coverage (-0.37), combined with ongoing operational execution challenges and transformation costs, point to persistent unprofitability and financial strain.

NEOG at a glance

Market value	$2.6B
Revenue growth (year over year)	-0.3%
Profit margin	-6.3%
Debt / equity	0.37

Every AI call on NEOG since July 27, 2026, and what happened next (18 calls) →

Research of October 13, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.